Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors
- PMID: 19505924
- DOI: 10.1158/1055-9965.EPI-08-1173
Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors
Abstract
Purpose: Circulating tumor cells (CTC) have been recently accepted by the Food and Drug Administration of the United States as a prognostic tool in advanced prostate cancer. However, a number of questions remain about the use of the test. The optimal clinical cut-off has never been determined. Also, the predictive value of CTCs in the setting of low-burden advanced prostate cancer has not been evaluated. Herein we describe our experience with the CellSearch method of CTC enumeration.
Experimental design: CTCs enumerated from 100 patients with castration-resistant prostate cancer were correlated with clinicopathologic characteristics and conventional biomarkers, such as prostate-specific antigen and lactate dehydrogenase. Patients received ongoing medical oncologic follow-up for up to 26 months, and overall survival status was documented.
Results: Forty-nine of the patients (49%) were alive at the end of the study. CTC counts correlate well with overall survival (P < 0.001) but are also tightly interrelated to other biomarkers. Threshold analysis identified 4 CTC/7.5 cc (compared with the approved value of 5) as an optimal cut-off value with respect to correlation with survival outcomes as well as predictive of metastatic disease. Univariate analysis confirmed a tight interrelationship between cut-off CTC values and biomarkers. Multivariate analysis with bootstrap sampling validation identified lactate dehydrogenase (P = 0.002) and CTCs (P = 0.001) as independently prognostically significant.
Conclusions: Baseline CTC values provide important prognostic information and specific prediction of metastatic disease. Their presence correlates with classic biomarkers.
Similar articles
-
Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.Clin Genitourin Cancer. 2011 Sep;9(1):31-8. doi: 10.1016/j.clgc.2011.04.001. Epub 2011 Jun 25. Clin Genitourin Cancer. 2011. PMID: 21705286
-
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.Clin Cancer Res. 2007 Dec 1;13(23):7053-8. doi: 10.1158/1078-0432.CCR-07-1506. Clin Cancer Res. 2007. PMID: 18056182
-
Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.Urol Oncol. 2015 Mar;33(3):110.e1-9. doi: 10.1016/j.urolonc.2014.09.002. Epub 2015 Jan 13. Urol Oncol. 2015. PMID: 25595577
-
Using circulating tumor cells as a prognostic indicator in metastatic castration-resistant prostate cancer.Clin J Oncol Nurs. 2012 Apr;16(2):E44-7. doi: 10.1188/12.CJON.E44-E47. Clin J Oncol Nurs. 2012. PMID: 22459536 Review.
-
The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer.Future Oncol. 2012 Mar;8(3):321-31. doi: 10.2217/fon.12.3. Future Oncol. 2012. PMID: 22409467 Review.
Cited by
-
Isolated, disseminated and circulating tumour cells in prostate cancer.Nat Rev Urol. 2012 Aug;9(8):448-63. doi: 10.1038/nrurol.2012.136. Epub 2012 Jul 10. Nat Rev Urol. 2012. PMID: 22777287 Review.
-
Circulating tumor cells: biology and clinical significance.Signal Transduct Target Ther. 2021 Nov 22;6(1):404. doi: 10.1038/s41392-021-00817-8. Signal Transduct Target Ther. 2021. PMID: 34803167 Free PMC article. Review.
-
Prognostic determinants in prostate cancer.Cancer J. 2011 Nov-Dec;17(6):429-37. doi: 10.1097/PPO.0b013e31823b042c. Cancer J. 2011. PMID: 22157287 Free PMC article. Review.
-
Circulating tumors cells as biomarkers: progress toward biomarker qualification.Cancer J. 2011 Nov-Dec;17(6):438-50. doi: 10.1097/PPO.0b013e31823e69ac. Cancer J. 2011. PMID: 22157288 Free PMC article. Review.
-
Clinical utility of a circulating tumor cell assay in Merkel cell carcinoma.J Am Acad Dermatol. 2014 Mar;70(3):449-55. doi: 10.1016/j.jaad.2013.10.051. Epub 2013 Dec 31. J Am Acad Dermatol. 2014. PMID: 24388423 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical